MA16.06 Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN

In the Phase 3, open-label CASPIAN study, first-line durvalumab (anti-PD-L1) + etoposide and cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) (data cut-off [DCO]: Mar 11, 2019): HR 0.73 (95% CI 0.59–0.91; p=0.0047). This benefit was sustained with >2 years of median follow-up (DCO: Jan 27, 2020): HR 0.75 (95% CI 0.62‒0.91; nominal p=0.0032). Although not statistically significant, a numerical improvement in OS was observed with durvalumab + tremelimumab (anti-CTLA-4) + EP versus EP: HR 0.82 (95% CI 0.68‒1.00; p=0.0451).